Abstract | AIM: METHODS: In this multicenter, randomized, double-blind, placebo-controlled phase II study, patients received apararenone 10 mg or placebo once daily for 72 weeks. The primary efficacy end-point was percent change in serum alanine aminotransferase (ALT) from baseline to 24 weeks after randomization. Secondary efficacy end-points included changes in liver fibrosis markers. Adverse drug reactions (ADRs) and serum potassium levels were evaluated. RESULTS: CONCLUSIONS: In patients with NASH, apararenone 10 mg/day for 72 weeks was effective in decreasing ALT levels, improved multiple potential fibrosis markers, and was safe and well tolerated. Pathological findings showed anti-inflammatory and antifibrotic effects of apararenone.
|
Authors | Takeshi Okanoue, Michiie Sakamoto, Kenichi Harada, Masaya Inagaki, Naoko Totsuka, Gaia Hashimoto, Hiromitsu Kumada |
Journal | Hepatology research : the official journal of the Japan Society of Hepatology
(Hepatol Res)
Vol. 51
Issue 9
Pg. 943-956
(Sep 2021)
ISSN: 1386-6346 [Print] Netherlands |
PMID | 34260795
(Publication Type: Journal Article)
|
Copyright | © 2021 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology. |